Inari Medical (NARI) Scheduled to Post Earnings on Tuesday

Inari Medical (NASDAQ:NARI) is set to announce its earnings results after the market closes on Tuesday, April 30th. Analysts expect the company to announce earnings of ($0.16) per share for the quarter. Inari Medical has set its FY 2024 guidance at EPS.Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Inari Medical (NASDAQ:NARI) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.09). Inari Medical had a positive return on equity of 1.23% and a negative net margin of 0.33%. The business had revenue of $132.10 million during the quarter, compared to analysts’ expectations of $131.82 million. During the same period in the previous year, the company posted ($0.11) EPS. Inari Medical’s revenue for the quarter was up 22.5% on a year-over-year basis. On average, analysts expect Inari Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Inari Medical Stock Performance

Shares of NARI opened at $38.42 on Friday. The company has a 50 day moving average price of $44.86 and a 200-day moving average price of $54.33. Inari Medical has a fifty-two week low of $36.73 and a fifty-two week high of $71.85. The stock has a market capitalization of $2.23 billion, a PE ratio of -1,280.67 and a beta of 0.84.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $75.00 price target on shares of Inari Medical in a research report on Friday, April 12th. Piper Sandler cut shares of Inari Medical from an “overweight” rating to a “neutral” rating and lowered their price target for the stock from $85.00 to $55.00 in a research report on Thursday, February 29th. Needham & Company LLC reaffirmed a “buy” rating and issued a $72.00 price target on shares of Inari Medical in a research report on Wednesday, March 6th. Finally, Truist Financial decreased their target price on shares of Inari Medical from $61.00 to $52.00 and set a “hold” rating for the company in a research report on Friday, March 22nd. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $73.71.

Insider Activity at Inari Medical

In related news, Director William Hoffman sold 1,451 shares of the stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $40.00, for a total transaction of $58,040.00. Following the completion of the sale, the director now owns 999,782 shares of the company’s stock, valued at $39,991,280. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Inari Medical news, CFO Mitch C. Hill sold 6,000 shares of the firm’s stock in a transaction on Friday, April 12th. The shares were sold at an average price of $40.96, for a total value of $245,760.00. Following the completion of the transaction, the chief financial officer now owns 181,294 shares of the company’s stock, valued at $7,425,802.24. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director William Hoffman sold 1,451 shares of the firm’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $40.00, for a total transaction of $58,040.00. Following the completion of the transaction, the director now directly owns 999,782 shares of the company’s stock, valued at approximately $39,991,280. The disclosure for this sale can be found here. Insiders sold 47,451 shares of company stock valued at $1,949,000 over the last 90 days. Insiders own 10.60% of the company’s stock.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.